These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

953 related items for PubMed ID: 20204355

  • 1. Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging.
    Heusner TA, Kuemmel S, Koeninger A, Hamami ME, Hahn S, Quinsten A, Bockisch A, Forsting M, Lauenstein T, Antoch G, Stahl A.
    Eur J Nucl Med Mol Imaging; 2010 Jun; 37(6):1077-86. PubMed ID: 20204355
    [Abstract] [Full Text] [Related]

  • 2. Assessment of multifocality and axillary nodal involvement in early-stage breast cancer patients using 18F-FDG PET/CT compared to contrast-enhanced and diffusion-weighted magnetic resonance imaging and sentinel node biopsy.
    Ergul N, Kadioglu H, Yildiz S, Yucel SB, Gucin Z, Erdogan EB, Aydin M, Muslumanoglu M.
    Acta Radiol; 2015 Aug; 56(8):917-23. PubMed ID: 25013091
    [Abstract] [Full Text] [Related]

  • 3. Newly diagnosed lymphoma: initial results with whole-body T1-weighted, STIR, and diffusion-weighted MRI compared with 18F-FDG PET/CT.
    van Ufford HM, Kwee TC, Beek FJ, van Leeuwen MS, Takahara T, Fijnheer R, Nievelstein RA, de Klerk JM.
    AJR Am J Roentgenol; 2011 Mar; 196(3):662-9. PubMed ID: 21343511
    [Abstract] [Full Text] [Related]

  • 4. Whole-body diffusion-weighted imaging: the added value to whole-body MRI at initial diagnosis of lymphoma.
    Gu J, Chan T, Zhang J, Leung AY, Kwong YL, Khong PL.
    AJR Am J Roentgenol; 2011 Sep; 197(3):W384-91. PubMed ID: 21862763
    [Abstract] [Full Text] [Related]

  • 5. Whole-body MRI with diffusion-weighted imaging: a valuable alternative to contrast-enhanced CT for initial staging of aggressive lymphoma.
    Balbo-Mussetto A, Cirillo S, Bruna R, Gueli A, Saviolo C, Petracchini M, Fornari A, Lario CV, Gottardi D, De Crescenzo A, Tarella C.
    Clin Radiol; 2016 Mar; 71(3):271-9. PubMed ID: 26749081
    [Abstract] [Full Text] [Related]

  • 6. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
    Schmidt H, Brendle C, Schraml C, Martirosian P, Bezrukov I, Hetzel J, Müller M, Sauter A, Claussen CD, Pfannenberg C, Schwenzer NF.
    Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
    [Abstract] [Full Text] [Related]

  • 7. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
    Giraudo C, Raderer M, Karanikas G, Weber M, Kiesewetter B, Dolak W, Simonitsch-Klupp I, Mayerhoefer ME.
    Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
    [Abstract] [Full Text] [Related]

  • 8. Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CT.
    Michielsen K, Vergote I, Op de Beeck K, Amant F, Leunen K, Moerman P, Deroose C, Souverijns G, Dymarkowski S, De Keyzer F, Vandecaveye V.
    Eur Radiol; 2014 Apr; 24(4):889-901. PubMed ID: 24322510
    [Abstract] [Full Text] [Related]

  • 9. Ionising radiation-free whole-body MRI versus (18)F-fluorodeoxyglucose PET/CT scans for children and young adults with cancer: a prospective, non-randomised, single-centre study.
    Klenk C, Gawande R, Uslu L, Khurana A, Qiu D, Quon A, Donig J, Rosenberg J, Luna-Fineman S, Moseley M, Daldrup-Link HE.
    Lancet Oncol; 2014 Mar; 15(3):275-85. PubMed ID: 24559803
    [Abstract] [Full Text] [Related]

  • 10. Whole-body diffusion-weighted imaging compared with FDG-PET/CT in staging of lymphoma patients.
    Abdulqadhr G, Molin D, Aström G, Suurküla M, Johansson L, Hagberg H, Ahlström H.
    Acta Radiol; 2011 Mar 01; 52(2):173-80. PubMed ID: 21498346
    [Abstract] [Full Text] [Related]

  • 11. Whole-body diffusion-weighted imaging vs. FDG-PET for the detection of non-small-cell lung cancer. How do they measure up?
    Chen W, Jian W, Li HT, Li C, Zhang YK, Xie B, Zhou DQ, Dai YM, Lin Y, Lu M, Huang XQ, Xu CX, Chen L.
    Magn Reson Imaging; 2010 Jun 01; 28(5):613-20. PubMed ID: 20418042
    [Abstract] [Full Text] [Related]

  • 12. Detection of bone metastases in non-small cell lung cancer patients: comparison of whole-body diffusion-weighted imaging (DWI), whole-body MR imaging without and with DWI, whole-body FDG-PET/CT, and bone scintigraphy.
    Takenaka D, Ohno Y, Matsumoto K, Aoyama N, Onishi Y, Koyama H, Nogami M, Yoshikawa T, Matsumoto S, Sugimura K.
    J Magn Reson Imaging; 2009 Aug 01; 30(2):298-308. PubMed ID: 19629984
    [Abstract] [Full Text] [Related]

  • 13. Diffusion-weighted MR imaging in comparison to integrated [¹⁸F]-FDG PET/CT for N-staging in patients with lung cancer.
    Pauls S, Schmidt SA, Juchems MS, Klass O, Luster M, Reske SN, Brambs HJ, Feuerlein S.
    Eur J Radiol; 2012 Jan 01; 81(1):178-82. PubMed ID: 20932700
    [Abstract] [Full Text] [Related]

  • 14. Diagnostic value of diffusion-weighted imaging in simultaneous 18F-FDG PET/MR imaging for whole-body staging of women with pelvic malignancies.
    Grueneisen J, Schaarschmidt BM, Beiderwellen K, Schulze-Hagen A, Heubner M, Kinner S, Forsting M, Lauenstein T, Ruhlmann V, Umutlu L.
    J Nucl Med; 2014 Dec 01; 55(12):1930-5. PubMed ID: 25453042
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of ¹⁸F-FDG PET/MRI, ¹⁸F-FDG PET/CT, MRI, and CT in whole-body staging of recurrent breast cancer.
    Sawicki LM, Grueneisen J, Schaarschmidt BM, Buchbender C, Nagarajah J, Umutlu L, Antoch G, Kinner S.
    Eur J Radiol; 2016 Feb 01; 85(2):459-65. PubMed ID: 26781152
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of PET and MR datasets in integrated 18F-FDG PET/MRI: A comparison of different MR sequences for whole-body restaging of breast cancer patients.
    Grueneisen J, Sawicki LM, Wetter A, Kirchner J, Kinner S, Aktas B, Forsting M, Ruhlmann V, Umutlu L.
    Eur J Radiol; 2017 Apr 01; 89():14-19. PubMed ID: 28267530
    [Abstract] [Full Text] [Related]

  • 17. 18F-FDG PET/CT and whole-body MRI diagnostic performance in M staging for non-small cell lung cancer: a systematic review and meta-analysis.
    Machado Medeiros T, Altmayer S, Watte G, Zanon M, Basso Dias A, Henz Concatto N, Hoefel Paes J, Mattiello R, de Souza Santos F, Mohammed TL, Verma N, Hochhegger B.
    Eur Radiol; 2020 Jul 01; 30(7):3641-3649. PubMed ID: 32125513
    [Abstract] [Full Text] [Related]

  • 18. Diagnostic performance of FDG-PET/MRI and WB-DW-MRI in the evaluation of lymphoma: a prospective comparison to standard FDG-PET/CT.
    Herrmann K, Queiroz M, Huellner MW, de Galiza Barbosa F, Buck A, Schaefer N, Stolzman P, Veit-Haibach P.
    BMC Cancer; 2015 Dec 23; 15():1002. PubMed ID: 26699124
    [Abstract] [Full Text] [Related]

  • 19. Diagnostic accuracy of whole-body PET/MRI and whole-body PET/CT for TNM staging in oncology.
    Heusch P, Nensa F, Schaarschmidt B, Sivanesapillai R, Beiderwellen K, Gomez B, Köhler J, Reis H, Ruhlmann V, Buchbender C.
    Eur J Nucl Med Mol Imaging; 2015 Jan 23; 42(1):42-8. PubMed ID: 25112399
    [Abstract] [Full Text] [Related]

  • 20. Diffusion-weighted imaging as part of hybrid PET/MRI protocols for whole-body cancer staging: does it benefit lesion detection?
    Buchbender C, Hartung-Knemeyer V, Beiderwellen K, Heusch P, Kühl H, Lauenstein TC, Forsting M, Antoch G, Heusner TA.
    Eur J Radiol; 2013 May 23; 82(5):877-82. PubMed ID: 23428414
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.